Feb 28, 2022 / 05:00PM GMT
Operator
Ladies and gentlemen, welcome to the AB Science web conference. I will now hand over the call to Alain Moussy, Olivier Hermine, Laurent Guy. Gentlemen, please go ahead.
Alain Moussy - AB Science S.A. - Co-Founder, Chairman, President, CEO, MD & Scientific Director
Thank you. Good evening, and good afternoon. This is Alain Moussy, CEO of AB Science. With me this evening, there is Laurent Guy, the Financial Director of AB Science; and Professor Olivier Hermine, who is the President of the Scientific Committee of AB Science. The topic this evening is to walk you through the recent news on the recent Health Canada accessibility to file masitinib in the treatment of ALS under the NOC/c procedure. And also to walk you through the different updates across indications of the masitinib program and also the 8939 compound program.
And naturally, as usual, I will deliver a presentation. And after this presentation, you will have the opportunity to ask questions either by oral or by writing. I'll share the disclaimer. And then we can enter into the first part of
AB Science SA To Discuss the Masitinib Filing in the Treatment of ALS in Canada and Update on Clinical Program in all indications Call Transcript
Feb 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers